Add a Long-Acting Beta-Agonist (LABA) to Incruse
For a patient experiencing persistent symptoms on Incruse (umeclidinium) monotherapy, add a long-acting beta-agonist (LABA) to create dual bronchodilator therapy with a LAMA/LABA combination. This is the most direct and evidence-based escalation strategy supported by both GOLD guidelines and FDA-approved combination products 1, 2.
Recommended Medication Options
The preferred approach is switching to a single-inhaler combination rather than adding a separate LABA inhaler:
- Umeclidinium/vilanterol (Anoro Ellipta) 62.5/25 mcg once daily - This maintains the same LAMA (umeclidinium from Incruse) while adding vilanterol (LABA) in a convenient once-daily formulation 3
Alternative LAMA/LABA combinations include:
- Indacaterol/glycopyrronium (Ultibro)
- Tiotropium/olodaterol
- Aclidinium/formoterol
Evidence Supporting This Approach
Dual bronchodilator therapy (LAMA + LABA) consistently demonstrates superior outcomes compared to monotherapy in symptomatic COPD patients 1. The GOLD guidelines explicitly recommend LAMA/LABA combination as the escalation step for patients with persistent symptoms on single-agent bronchodilator therapy 2.
Specific evidence for umeclidinium/vilanterol shows:
- Improved lung function: Increases trough FEV1 by 88-90 mL compared to LAMA monotherapy 4
- Symptom reduction: 63% of patients achieved clinically meaningful dyspnea improvement (TDI ≥1 unit) versus 49% on tiotropium alone 4
- Reduced rescue medication use: 0.1 fewer puffs per day 4
- Rapid onset: Improvements in FEV1 observed within 5 minutes on Day 1 4
Clinical Algorithm
Step 1: Verify the patient is using Incruse correctly (proper inhaler technique, daily adherence)
Step 2: Confirm COPD diagnosis and symptom burden (mMRC ≥1 or CAT score ≥10)
Step 3: Switch from Incruse monotherapy to umeclidinium/vilanterol combination once daily
Step 4: Reassess in 4-12 weeks for symptom improvement and lung function
Step 5: If symptoms persist despite LAMA/LABA, consider:
- Adding ICS if patient has ≥2 exacerbations per year or blood eosinophils ≥300 cells/μL
- Triple therapy (LAMA/LABA/ICS) for high-risk patients 1, 2
Important Caveats
Do not simply increase the Incruse dose - the FDA label explicitly states that increasing the daily dose beyond the recommended 62.5 mcg is not appropriate for inadequate symptom control 3. Bronchodilators have a flat dose-response curve with little additional benefit but increased toxicity at higher doses 1.
Avoid adding ICS as the next step unless the patient has frequent exacerbations (≥2 per year). For purely symptomatic patients without exacerbation history, LAMA/LABA is superior to LAMA/ICS combinations 1, 2.
Monitor for LABA side effects: tachycardia, tremor, hypokalemia, though these are generally well-tolerated at therapeutic doses 1.
The safety profile of umeclidinium/vilanterol is favorable, with adverse event rates (28-30%) similar to monotherapy and no clinically significant cardiovascular concerns 4, 5, 6.